Anti-IL-23p19 therapy inhibits the adoptive transfer of syngeneic graft-versus-host disease

J. Anthony Brandon, C. Darrell Jennings, Alan M. Kaplan, J. Scott Bryson

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Syngeneic graft-versus-host disease (SGVHD), a chronic inflammatory disease, develops following irradiation, syngeneic bone marrow transplantation (BMT) and treatment with the immunosuppressive agent cyclosporine A (CsA). We have shown that TH1 and TH17 cytokine responses are increased during the development of SGVHD. The current study was designed to further investigate the involvement of TH17 immunity in SGVHD-associated colitis. IL-23 is a TH17 cytokine responsible for maintaining the effector functions of TH17 cells. The administration of anti-mouse IL-23p19 was shown to significantly reduce the clinical symptoms of primary and secondary SGVHD-associated colitis resulting in a significant reduction in both TH1 and TH17 associated cytokine expression. These results demonstrate that the TH17-associated cytokine, IL-23, may prove to be a beneficial therapeutic target in the treatment of chronic colon inflammation.

Original languageEnglish
Pages (from-to)732-735
Number of pages4
Issue number3
StatePublished - Mar 2013


  • CD4 T cells
  • Cyclosporine A
  • Interleukin-23
  • Mucosal inflammation
  • Transplantation

ASJC Scopus subject areas

  • Molecular Biology
  • Hematology
  • Biochemistry
  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Anti-IL-23p19 therapy inhibits the adoptive transfer of syngeneic graft-versus-host disease'. Together they form a unique fingerprint.

Cite this